Table 1. Incident use in community-dwelling older adults (65+).
Medications | SGAs | FGAs | BZDs/ZOP, ZAL | BZDs/ZOP, ZAL + SGA |
---|---|---|---|---|
Users/1,000 Year 1998 | 0.21 | 1.88 | 13.14 | 0.06 |
Users/1,000 Year 2009 | 1.63 | 1.03 | 13.66 | 0.15 |
Change in rate per quarter | 1.02* | 0.98* | 1.00 NS | 1.01* |
Age effect 65–84 vs. 85+ | 0.44* | 0.85* | 1.08* | 0.60* |
SES effect low vs. high | 1.10* | 1.14* | 1.00 NS | 1.09 NS |
Region effect rural vs. urban | 0.88* | 1.51* | 1.01 NS | 1.02 NS |
Sex effect male vs. female | 0.91* | 0.86* | 0.73* | 1.17* |
Notes.
Results for change in quarterly rate, age, SES, region and sex effects are presented as relative rates (adjusted for age, SES, region, sex and time).
- SGAs
- second generation antipsychotics
- FGAs
- first generation antipsychotics
- BZDs/ZOP, ZAL
- benzodiazepines, zopiclone, zaleplon
- NS
- not significant
- SES
- socioeconomic status
Indicates a statistically significant effect (p < 0.05).